$0.03
4.20%
Nasdaq, Sep 04, 09:30 pm CET
ISIN
US0076242082
Symbol
ADXS

Advaxis, Inc. Stock price

$0.03
-0.00 4.03% 1M
+0.00 11.00% 6M
+0.01 23.33% YTD
+0.01 66.50% 1Y
-3.35 99.01% 3Y
-35.17 99.91% 5Y
-16,319.97 100.00% 10Y
-31,499.81 100.00% 20Y
Nasdaq, Closing price Fri, Sep 05 2025
+0.00 0.00%
ISIN
US0076242082
Symbol
ADXS
Industry

Key metrics

Basic
Market capitalization
$1.4m
Enterprise Value
$4.4m
Net debt
-
Cash
-
Shares outstanding
-
Valuation (TTM | estimate)
P/E
negative | -
P/S
142.0 | -
EV/Sales
435.0 | -
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-147.3%
Return on Equity
196.9%
ROCE
-
ROIC
-
Debt/Equity
-
Financials (TTM | estimate)
Revenue
- | -
EBITDA
- | -
EBIT
- | -
Net Income
- | -
Free Cash Flow
-
Growth (TTM | estimate)
Revenue
- | -
EBITDA
- | -
EBIT
- | -
Net Income
- | -
Free Cash Flow
-
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
-
FCF per Share
-
Short interest
1.4%
Employees
-
Rev per Employee
-
Show more

Is Advaxis, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

Advaxis, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Advaxis, Inc. forecast:

3x Hold
50%
3x Sell
50%

Analyst Opinions

6 Analysts have issued a Advaxis, Inc. forecast:

Hold
50%
Sell
50%

Financial data from Advaxis, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Dec '23
+/-
%
0.01 0.01
96% 96%
100%
- Direct Costs 0.01 0.01
-
100%
- -
-
-
- Selling and Administrative Expenses 12 12
43% 43%
121,800%
- Research and Development Expense 24 24
216% 216%
240,800%
-36 -36
126% 126%
-359,000%
- Depreciation and Amortization 0.37 0.37
61% 61%
3,700%
EBIT (Operating Income) EBIT -36 -36
125% 125%
-362,710%
Net Profit -48 -48
212% 212%
-480,700%

In millions USD.

Don't miss a Thing! We will send you all news about Advaxis, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Advaxis, Inc. is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. It has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy. The company was founded on June 5, 1987 and is headquartered in Princeton, NJ.

Head office United States
CEO Ken Berlin
Founded 2017
Website ayalapharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today